Mirati

Mirati Therapeutics

This oncology company develops targeted therapies for patients with cancers driven by genetic mutations, including a marketed inhibitor for non-small cell lung cancer.

Kinnate Biopharma

The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

Crossfire Oncology

This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.

Accent Therapeutics

This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.